Buy & Sell Synopsys, Inc. (SNPS) – Synopsys, Inc. Price Today
Aura AI Summary
Key Stats
- $95.58BMarket Cap
- TechnologySector
- -15.17%3M Drawdown
- $104.24BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 77 daysTypical Hold Time
Synopsys, Inc. (SNPS) is currently valued at a market capitalization of $95.58B, with an enterprise value of $104.24B. Over the past 52 weeks, Synopsys, Inc. has traded between a low of $380.47 and a high of $645.59, highlighting its annual price range. Over the past three months, Synopsys, Inc. has recorded a drawdown of -15.17%, reflecting recent price volatility. On average, investors hold Synopsys, Inc. for approximately 77 days, indicating typical investor behavior on the platform.
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Most Recent News
BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting
BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonst...
BioNTech reveals promising late-stage cancer drug data at ASCO 2026, advancing treatments for lung and ovarian cancers.
BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell ...
Africa's alternative lending market to grow to $8.1B by 2029, driven by digital credit and regulatory reforms.
Africa's alternative lending market is projected to grow from $4.8 billion in 2025 to $8.1 billion by 2029, with a CAGR of 13.9%. Growth is fueled by expanding digital credit via mobile money, tighter regulations in Nigeria, Kenya, and Ghana, and inc...